CLBT
Cellebrite DI Ltd. Technology - Digital Intelligence Investor Relations →
Cellebrite DI Ltd. (CLBT) closed at $14.27 as of 2026-03-20, trading 21.4% above its 200-week moving average of $11.75. The stock is currently moving closer to the line, down from 23.4% last week. The 14-week RSI sits at 31, indicating neutral momentum.
Trading volume is running at 1.3x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.27 ratio) is neutral — neither side is clearly dominating.
Over the past 232 weeks of data, CLBT has crossed below its 200-week moving average 4 times. On average, these episodes lasted 24 weeks. Historically, investors who bought CLBT at the start of these episodes saw an average one-year return of +79.9%.
With a market cap of $3.6 billion, CLBT is a mid-cap stock. The company generates a free cash flow yield of 4.0%. Return on equity stands at 19.1%, a solid level. The stock trades at 7.3x book value.
Share count has increased 28.8% over three years, indicating dilution. CLBT passes our Buffett quality screen: high return on equity, low debt, and positive free cash flow.
Over the past 4.5 years, a hypothetical investment of $100 in CLBT would have grown to $128, compared to $150 for the S&P 500. CLBT has returned 5.6% annualized vs 9.5% for the index, underperforming the broader market over this period.
Free cash flow has been growing at a 140.7% compound annual rate, with 4 consecutive years of positive cash generation.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: CLBT vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After CLBT Crosses Below the Line?
Across 4 historical episodes, buying CLBT when it crossed below its 200-week moving average produced an average return of +78.2% after 12 months (median +126.0%), compared to +21.8% for the S&P 500 over the same periods. 75% of those episodes were profitable after one year. After 24 months, the average return was +91.8% vs +43.0% for the index.
Each line shows $100 invested at the moment CLBT crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
CLBT has crossed below its 200-week MA 4 times with an average 1-year return of +79.9% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Nov 2021 | Jul 2023 | 87 | 52.5% | -50.1% | +54.1% |
| Jul 2023 | Aug 2023 | 1 | 0.3% | +75.6% | +93.1% |
| Sep 2023 | Sep 2023 | 1 | 0.5% | +136.9% | +93.1% |
| Oct 2023 | Nov 2023 | 5 | 13.1% | +157.3% | +103.3% |
| Average | 24 | — | +79.9% | — |
Frequently Asked Questions
Is CLBT below its 200-week moving average?
No. Cellebrite DI Ltd. (CLBT) is currently 21.4% above its 200-week moving average of $11.75. It would need to fall to $11.75 to cross below the line.
What is CLBT's 200-week moving average price?
Cellebrite DI Ltd.'s 200-week moving average is $11.75 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when CLBT drops below its 200-week moving average?
CLBT has crossed below its 200-week moving average 4 times in our data. On average, buying at that moment produced a one-year return of +79.9%. These dips have historically been decent entry points. These episodes lasted 24 weeks on average.
Is CLBT a good value right now?
Here's what our data says about CLBT as of 2026-03-20: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 31. Free cash flow yield is 4.0%. Return on equity is 19.1%. Price-to-book is 7.3x. This is not a buy or sell recommendation — always do your own research.
How does CLBT compare to the S&P 500?
Over the past 4.5 years, $100 invested in CLBT would have grown to $128, compared to $150 for the S&P 500. That's 5.6% annualized vs 9.5% for the index. CLBT has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20